Osborne Clarke has advised Elixirr on its move from AIM to the Official List and admission to trading on the Main Market. Elixirr international plc, described...
Elixirr Transitions from AIM to Main Market Listing with £325 Million Valuation
PharosAI’s Joint Venture To Boost AI-Assisted Cancer Care
Osborne Clarke advised PharosAI on the deal. PharosAI, a joint venture between four London-based life sciences research institutions, is poised to revolutionize cancer care by unlocking...
Bloomsbury Genetic Therapies Limited’s £5 Million Seed Financing
Osborne Clarke advised UCL Technology Fund on the investment. Bloomsbury Genetic Therapies Limited (“Bloomsbury”), a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from...
Nexeon’s US$80 Million Funding
Osborne Clarke has advised Nexeon on the deal. Nexeon was granted significant US$80 million investment from a consortium including SKC Co. Ltd (SKC), SJL Partners LLC...
MML Capital’s £90 Million Investment In Western Global
Osborne Clarke has advised the shareholders and management team of Western Global on the deal. With MML’s support, Western Global will continue its strong growth trajectory...